Solifenacin

Solifenacin, sold as the brand name Vesicare among others, is a medication used to treat overactive bladder and neurogenic detrusor overactivity (NDO). It may help with incontinence, urinary frequency, and urinary urgency. Benefits appear similar to other medications in the class. It is taken by mouth. Common side effects include dry mouth, constipation, and urinary tract infection. Severe side effects may include urinary retention, QT prolongation, hallucinations, glaucoma, and anaphylaxis. It is unclear if use is safe during pregnancy. It is of the antimuscarinic class and works by decreasing bladder contractions. Solifenacin was approved for medical use in the United States in 2004. In 2023, it was the 245th most commonly prescribed medication in the United States, with more than 1 million prescriptions.